|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
IPATential150 Trial in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
|
|
Cora Sternberg MD, FACP
|
| In this conversation with Alicia Morgans, Cora Sternberg, co-investigator of phase III IPATential150 trial, highlights the data on the IPATential150 trial presented at the ASCO GU 2021 meeting that looked at an exploratory analysis evaluating putative biomarker associations with radiographic progression-free survival.
|
|
|
|
|
|
|
|
|
|
|
|
| Sequential Radium-223 Treatment of mCRPC That Progressed After First-Line Novel Antihormonal Therapy, A Real-World Clinical Outcomes Study |
| A. Oliver Sartor, MD |
| Oliver Sartor joins Alicia Morgans to discuss a real-world clinical outcomes study of sequential novel antihormonal therapy (abiraterone or enzalutamide) or radium-223 (Ra-223) treatment of metastatic castration-resistant prostate cancer (mCRPC) that progressed after first-line NAH. |
|
|
|
|
|
|
|
|
|
|
|
| PI3K/AKT Pathway Biomarkers Analysis From The Phase III IPATential150 Trial Of Ipatasertib Plus Abiraterone In Metastatic Castration-Resistant Prostate Cancer |
| Johann de Bono, MB, ChB, FRCP, MSc, Ph.D., FMedSci. |
| In this study, Johann de Bono presents an evaluation of several questions regarding the IPATential150 Trial. (1) What is the impact of differential IHC PTEN loss status cutoffs on treatment efficacy, (2) What is the concordance between PTEN assessment by immunohistochemistry and next generation sequencing (NGS), (3) How does PTEN loss by next generation sequencing relate to outcomes, and (4) How do other genomic alterations in the PI3K/AKT pathway associate with treatment outcomes with ipatasertib. |
|
|
|
|
|
| Back to Basics in Personalization: Returning to PTEN |
| Martin Gleave, MD, FRCSC, FACS |
| Martin Gleave discussed alteration in the PI3K signaling pathway as an important molecular subtype of metastatic castration-resistant prostate cancer. Dr. Gleave summarized that PI3K pathway activation via multiple mechanisms is common in prostate cancer. Randomized trials of AKT inhibitors with abiraterone have shown some clinical benefit, but also significant toxicity. |
|
|
|
|
|
| Beyond the Basics: Harnessing the Immune System to Fight Prostate Cancer |
| Karen A. Autio, MD, MSc |
| Karen Autio presented on the indications for immune checkpoint inhibitors in prostate cancer, what is known about the tumor immune milieu in prostate cancer, and discussed ongoing work to further harness the immune system in the fight against this disease. |
|
|
|
|
|
|
|
|
|
|
| Progress and Promise in Treatment Personalization for Advanced Prostate Cancer Panel Discussion |
| Peter Nelson, MD, Martin Gleave, MD, FRCSC, FACS, Karen A. Autio, MD, MSc, Mike Sathekge, MBChB, MMed (Nucl Med), Ph.D. |
| In this panel discussion, the presenters answered questions from the audience regarding their presentations on the progress and promise of treatment personalization for advanced prostate cancer. They discuss, predicting response to PARPi with prior response to platinum, irrespective of HRD status, as well as PARP inhibitor sensitivity and accuracy of biomarkers. |
|
|
|
|
|
| IPATential150: Phase III Study of Ipatasertib plus Abiraterone vs Placebo plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer |
| Johann de Bono, MB, ChB, FRCP, MSc, Ph.D., FMedSci. |
| In this presentation, Johann de Bono presented initial results of the IPATential150 trial. Dr. De Bono highlighted that this combination of ipatasertib, abiraterone acetate, and prednisone improves rPFS and other markers of anti-tumor activity in patients with previously untreated mCRPC, particularly among the poor-prognostic subgroup with PTEN-loss. |
|
|
|
|
|
| Novel Immunotherapy for Prostate Cancer - AMG 160 - PSMA-Targeted, Bispecific T-Cell Engager (BiTE®) Immune Therapy for Metastatic Castration-Resistant Prostate Cancer - Invited Discussant
|
| Cora Sternberg MD, FACP |
| Cora Sternberg provided an invited discussant presentation of novel research in prostate immunotherapy, AMG 160, PSMA-targeted bispecific t-cell engager immune therapy at this year's ESMO Virtual Congress. The recent emergence of BiTEs, T-cell engagers, CAR-T cells, and antibody-drug conjugates have provided renewed hope for immunotherapy in this disease space.
|
|
|
|
|
|
| High Throughput Assessment of Biomarkers in Tissue Microarrays Using Artificial Intelligence: PTEN Loss as a Proof-of-Principle in Multi-Center Prostate Cancer Cohorts - Beyond the Abstract |
| Tamara Jamaspishvili, MD, Ph.D. |
| Despite prostate cancer being one of the most commonly diagnosed diseases in men, the road to finding the cure is still hindered by several challenges. Successful management of post-operative patients is directly related to the accurate diagnosis and prognostication of prostate cancer. Over the years, many researchers around the world have put forward numerous molecular markers to aid in this process. However, none of these markers have been translated into clinical practice. |
|
|
|
|
|
|
|
|
|
|
|
